Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Child Neurol. 2011 Feb;26(2):228-30. doi: 10.1177/0883073810379639. Epub 2010 Sep 7.

Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1.

Author information

  • 1Department of Neurology, Children's Hospital Boston, Boston, MA 02446, USA. nicole.ullrich@childrens.harvard.edu

Abstract

Neurofibromatosis type 1 is a common multisystemic disorder that can result in tumors of the central and peripheral nervous system. Individuals with neurofibromatosis type 1 are also at increased risk to develop moyamoya syndrome, which is a cerebrovascular condition that predisposes affected individuals to develop strokes as a result of progressive narrowing of the intracranial internal carotid arteries and failure of adequate blood supply through collateral vessels. We report a case of a young boy with neurofibromatosis type 1 with glioblastoma who developed rapidly progressive moyamoya vasculopathy after treatment with the angiogenesis inhibitor bevacizumab.

PMID:
20823033
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk